Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BrainStorm presents biomarker analyses from NurOwn Phase 3 ALS trial » 12:03
10/07/22
10/07
12:03
10/07/22
12:03
BCLI

BrainStorm

$3.90 /

-0.19 (-4.65%)

BrainStorm Cell…

BrainStorm Cell Therapeuticsannounced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn in amyotrophic lateral sclerosis at the ongoing 5th Annual ALS ONE Research Symposium. The presentation was delivered by Dr. Stacy Lindborg, Chief Development Officer at Brainstorm, and entitled, "The Relationship between CSF Biomarkers and Efficacy of Treatment with NurOwn." NurOwn's Phase 3 trial is a strong outlier compared to other late-stage ALS trials due to the inclusion of participants with more advanced disease. The average ALSFRS-R score in NurOwn's Phase 3 trial was 31, 5 points lower than the registrational trial for the most recently FDA-approved therapy. The inclusion of more advanced participants impacts the assessment of all clinical endpoints based on the ALSFRS-R, as a result of the inability to measure ongoing clinical decline with scale in these participants. To draw valid conclusions from clinical endpoint data collected in the trial, the floor effect must be addressed. As previously announced, a NurOwn treatment effect was observed in participants in a pre-specified subgroup with less advanced disease across two endpoints: the primary endpoint and a key secondary endpoint. The difference between NurOwn and placebo for this key secondary endpoint was nominally statistically significant. An analysis was performed to evaluate the effects of NurOwn and placebo on cerebrospinal fluid biomarkers across pathways important to ALS of neuroinflammation, neurodegeneration and neuroprotection. Additional goals were to understand the role that baseline ALSFRS-R values plays on biomarker trajectories and to understand the predictive power of biomarkers on clinical outcomes. As observed in earlier trials, NurOwn was shown to decrease biomarkers associated with neuroinflammation and neurodegeneration, and increase neuroprotective biomarkers over 20 weeks, demonstrating its multifaceted mechanism of action. New analyses looked at the trajectory of biomarkers for the subgroups of participants with baseline ALSFRS-R scores greater than25 and less than or equal to25, those most likely to be impacted by the floor effect of the scale. Decreases in neuroinflammatory and neurodegenerative markers and increases in neuroprotective markers in NurOwn treated participants compared to placebo were observed in both subgroups. These results indicate that NurOwn had similar biological effects on ALS participants regardless of the level of disease progression at baseline. Further statistical modeling pre-specified prior to unblinding of the data identified three biomarkers that were predictive of clinical outcomes: baseline LAP, baseline neurofilament light and mean change in Galectin-1. These biomarkers relate to neuroinflammatory, neurodegenerative, and neuroprotective pathways, respectively.

ShowHide Related Items >><<
BCLI BrainStorm
$3.90 /

-0.19 (-4.65%)

BCLI BrainStorm
$3.90 /

-0.19 (-4.65%)

BCLI BrainStorm
$3.90 /

-0.19 (-4.65%)

Tuesday
Downgrade
Clene downgraded to Perform from Outperform at Oppenheimer » 07:58
10/04/22
10/04
07:58
10/04/22
07:58
CLNN

Clene

$2.01 /

-0.8 (-28.47%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell downgraded Clene to Perform from Outperform. The analyst notes that top-line Healey ALS Platform trial results revealed that mortality-adjusted ALSFRSR over 24 weeks showed almost no divergence for CNM-Au8 versus placebo, and slow vital capacity and Combined Assessment of Function and Survival failed to show significant improvement at 24 weeks. "Intriguingly," he adds, results showed over 90% reduction in 24-week risk of death and death/permanently assisted ventilation support survival benefit consistent with Phase 2 Rescue-ALS study observations. Gershell expects to see full data, including biomarker analyses, by year-end, and Clene expects to meet with FDA in the first half of 2023 to discuss a path forward.

ShowHide Related Items >><<
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

10/04/22 Canaccord
Clene price target lowered to $6 from $10 at Canaccord
10/04/22 Benchmark
Clene price target lowered to $11 from $25 at Benchmark
10/03/22 Benchmark
Clene will need time to pivot after Healey ALS data, says Benchmark
10/03/22 H.C. Wainwright
H.C. Wainwright sees 'silver lining' for Clene beyond 'negative headline' in ALS
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

Recommendations
Clene price target lowered to $6 from $10 at Canaccord » 07:25
10/04/22
10/04
07:25
10/04/22
07:25
CLNN

Clene

$2.01 /

-0.8 (-28.47%)

Canaccord analyst Sumant…

Canaccord analyst Sumant Kulkarni lowered the firm's price target on Clene to $6 from $10 and keeps a Buy rating on the shares. The analyst said due to the uncertainty created by the HEALEY pivotal data, we are lowering our probability of approval for CnM-Au8 from 35% to 25% and pushing out the potential launch year from 2024 to 2025.

ShowHide Related Items >><<
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

10/04/22 Benchmark
Clene price target lowered to $11 from $25 at Benchmark
10/03/22 Benchmark
Clene will need time to pivot after Healey ALS data, says Benchmark
10/03/22 H.C. Wainwright
H.C. Wainwright sees 'silver lining' for Clene beyond 'negative headline' in ALS
07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

Recommendations
Clene price target lowered to $11 from $25 at Benchmark » 06:44
10/04/22
10/04
06:44
10/04/22
06:44
CLNN

Clene

$2.01 /

-0.8 (-28.47%)

Benchmark analyst Bruce…

Benchmark analyst Bruce Jackson lowered the firm's price target on Clene to $11 from $25 and keeps a Buy rating on the shares now that a Phase 3 trial is "likely" for CNM-Au8 after the company reported yesterday data from the Healey ALS platform trial that showed CNM-Au8 missed the primary endpoint of adjusted ALSFRS-R and the secondary endpoints of CAFS and SVC at 24 weeks. His assumptions on the timeline to approval has been pushed out a few years, which necessitates a higher discount rate, and he has also increased the discount rates he applies to its other development programs in MS and PD in light of the current market conditions, which drives his lower price target.

ShowHide Related Items >><<
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

10/03/22 Benchmark
Clene will need time to pivot after Healey ALS data, says Benchmark
10/03/22 H.C. Wainwright
H.C. Wainwright sees 'silver lining' for Clene beyond 'negative headline' in ALS
07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
05/02/22 Canaccord
Clene initiated with a Buy at Canaccord
CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

CLNN Clene
$2.01 /

-0.8 (-28.47%)

Monday
Recommendations
Clene will need time to pivot after Healey ALS data, says Benchmark » 11:44
10/03/22
10/03
11:44
10/03/22
11:44
CLNN

Clene

$1.86 /

-0.95 (-33.81%)

Benchmark analyst Bruce…

Benchmark analyst Bruce Jackson noted that Clene reported that in the Healey ALS platform trial CNM-Au8 missed the primary endpoint of adjusted ALSFRS-R and the secondary endpoints of CAFS and SVC at 24 weeks, but a secondary endpoint for survival using the 30 mg dose demonstrated a greater than 90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks. While Clene had hoped to use the Healey ALS data to seek FDA approval for CNM-Au8, it will now require additional time to pivot its regulatory strategy given today's results, Jackson said. He continues to believe that "CNM-Au8 ultimately prevails," so he keeps a Buy rating on Clene shares with a $25 price target, though Jackson admits "it may take longer to reach the market than originally anticipated." In late Monday morning trading, Clene shares are down 94c, or 34%, to $1.85.

ShowHide Related Items >><<
CLNN Clene
$1.86 /

-0.95 (-33.81%)

CLNN Clene
$1.86 /

-0.95 (-33.81%)

10/03/22 H.C. Wainwright
H.C. Wainwright sees 'silver lining' for Clene beyond 'negative headline' in ALS
07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
05/02/22 Canaccord
Clene initiated with a Buy at Canaccord
11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
CLNN Clene
$1.86 /

-0.95 (-33.81%)

CLNN Clene
$1.86 /

-0.95 (-33.81%)

CLNN Clene
$1.86 /

-0.95 (-33.81%)

CLNN Clene
$1.86 /

-0.95 (-33.81%)

On The Fly
What You Missed This Week in EVs and Clean Energy » 11:28
10/03/22
10/03
11:28
10/03/22
11:28
RIDE

Lordstown Motors

$1.73 /

-0.095 (-5.21%)

, BP

BP

$30.07 /

+1.52 (+5.32%)

, HTZ

Hertz

$16.95 /

+0.635 (+3.89%)

, IE

Ivanhoe Electric

$8.68 /

+0.4 (+4.83%)

, LEV

Lion Electric

$3.03 /

+0.17 (+5.95%)

, TSLA

Tesla

$243.40 /

-21.94 (-8.27%)

, RIVN

Rivian Automotive

$31.46 /

-1.45 (-4.41%)

, JKS

JinkoSolar

$55.77 /

+0.4 (+0.72%)

, RUN

Sunrun

$28.74 /

+1.15 (+4.17%)

, FSLR

First Solar

$134.86 /

+2.56 (+1.93%)

, GM

General Motors

$32.86 /

+0.71 (+2.21%)

, QS

QuantumScape

$8.79 /

+0.385 (+4.58%)

, PRTA

Prothena

$62.61 /

+2.02 (+3.33%)

, LCID

Lucid Group

$13.69 /

-0.275 (-1.97%)

, LI

Li Auto

$23.51 /

+0.52 (+2.26%)

, F

Ford

$11.49 /

+0.26 (+2.32%)

Institutional investors…

ShowHide Related Items >><<
TSLA Tesla
$243.40 /

-21.94 (-8.27%)

RUN Sunrun
$28.74 /

+1.15 (+4.17%)

RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

QS QuantumScape
$8.79 /

+0.385 (+4.58%)

PRTA Prothena
$62.61 /

+2.02 (+3.33%)

LI Li Auto
$23.51 /

+0.52 (+2.26%)

LEV Lion Electric
$3.03 /

+0.17 (+5.95%)

LCID Lucid Group
$13.69 /

-0.275 (-1.97%)

JKS JinkoSolar
$55.77 /

+0.4 (+0.72%)

IE Ivanhoe Electric
$8.68 /

+0.4 (+4.83%)

HTZ Hertz
$16.95 /

+0.635 (+3.89%)

GM General Motors
$32.86 /

+0.71 (+2.21%)

FSLR First Solar
$134.86 /

+2.56 (+1.93%)

F Ford
$11.49 /

+0.26 (+2.32%)

BP BP
$30.07 /

+1.52 (+5.32%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

08/05/22 R.F. Lafferty
R.F. Lafferty keeps $1 target on Lordstown after Q2 results
05/10/22 R.F. Lafferty
Lordstown Motors downgraded to Sell from Hold at R.F. Lafferty
05/10/22 Deutsche Bank
Lordstown Motors price target lowered to $2 from $3 at Deutsche Bank
03/01/22 R.F. Lafferty
Lordstown Motors price target lowered to $4 from $7 at R.F. Lafferty
BP BP
$30.07 /

+1.52 (+5.32%)

09/26/22 JPMorgan
BP downgraded to Neutral from Overweight at JPMorgan
09/12/22 Piper Sandler
BP price target raised to $47 from $44 at Piper Sandler
08/17/22 Morgan Stanley
BP price target raised to 566 GBp from 540 GBp at Morgan Stanley
08/08/22 Berenberg
BP price target lowered to 500 GBp from 510 GBp at Berenberg
HTZ Hertz
$16.95 /

+0.635 (+3.89%)

08/10/22 Tigress Financial
Tigress Financial raises Hertz price target to $34 on favorable industry trends
07/29/22 Deutsche Bank
Hertz price target raised to $38 from $29 at Deutsche Bank
07/14/22 Morgan Stanley
Hertz price target lowered to $16 from $23 at Morgan Stanley
07/13/22 Deutsche Bank
Hertz price target lowered to $29 from $36 at Deutsche Bank
IE Ivanhoe Electric
$8.68 /

+0.4 (+4.83%)

09/28/22 Raymond James
Ivanhoe Electric initiated with an Outperform at Raymond James
08/18/22 JPMorgan
Ivanhoe Electric initiated with a Neutral at JPMorgan
07/25/22 Jefferies
Ivanhoe Electric initiated with a Buy at Jefferies
07/25/22 BMO Capital
Ivanhoe Electric initiated with an Outperform at BMO Capital
LEV Lion Electric
$3.03 /

+0.17 (+5.95%)

09/27/22 B. Riley
Lion Electric initiated with a Buy at B. Riley
08/24/22 Veritas
Lion Electric initiated with a Sell at Veritas
06/28/22 DA Davidson
Lion Electric initiated with a Buy at DA Davidson
06/10/22 Roth Capital
Lion Electric initiated with a Buy at Roth Capital
TSLA Tesla
$243.40 /

-21.94 (-8.27%)

10/05/22 Gordon Haskett
Musk has more Tesla to sell for Twitter deal, says Gordon Haskett
10/04/22 Morgan Stanley
Morgan Stanley expects Tesla shares to give back recent relative strength
10/03/22 JPMorgan
Tesla price target raised to $153 from $137 at JPMorgan
10/03/22 Oppenheimer
Tesla should be bought on any weakness following Q3 deliveries, says Oppenheimer
RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

10/04/22 Truist
Rivian Automotive's affirmed FY22 production outweighs Q3 shortfall, says Truist
09/28/22 Truist
Truist starts 'diversified mobility powerhouse' Rivian Automotive at Buy
09/28/22 Truist
Rivian Automotive initiated with a Buy at Truist
09/28/22 RBC Capital
RBC cuts Rivian target, production forecasts but stays Outperform
JKS JinkoSolar
$55.77 /

+0.4 (+0.72%)

09/29/22 HSBC
JinkoSolar initiated with a Buy at HSBC
08/24/22 GLJ Research
JinkoSolar price target lowered to $14.88 from $16.61 at GLJ Research
06/29/22 Roth Capital
Roth sees CBP requiring quartzite docs as 'major problem' for solar industry
03/24/22 UBS
JinkoSolar price target raised to $52 from $44 at UBS
RUN Sunrun
$28.74 /

+1.15 (+4.17%)

09/28/22 Northland
Northland starts Sunrun at Outperform, sees chance to add in recent pullback
09/28/22 Northland
Sunrun initiated with an Outperform at Northland
08/18/22 Morgan Stanley
Sunrun price target raised to $79 from $70 at Morgan Stanley
08/08/22 JPMorgan
Sunrun price target raised to $65 from $52 at JPMorgan
FSLR First Solar
$134.86 /

+2.56 (+1.93%)

09/28/22 Evercore ISI
First Solar upgraded to Outperform at Evercore ISI on IRA benefits
09/28/22 Evercore ISI
First Solar upgraded to Outperform from In Line at Evercore ISI
09/09/22 Susquehanna
First Solar price target raised to $175 from $120 at Susquehanna
09/07/22 Goldman Sachs
First Solar upgraded to Buy from Sell at Goldman Sachs
GM General Motors
$32.86 /

+0.71 (+2.21%)

10/05/22 Morgan Stanley
General Motors price target lowered to $30 from $42 at Morgan Stanley
10/05/22 Morgan Stanley
Morgan Stanley upgrades Ford to Overweight, prefers over General Motors
09/30/22 Morgan Stanley
U.S. recession, 'Tesla-friendly' IRA may force change at GM, says Morgan Stanley
09/28/22 Citi
General Motors price target lowered to $78 from $87 at Citi
QS QuantumScape
$8.79 /

+0.385 (+4.58%)

09/28/22 Truist
Truist starts QuantumScape at Hold, upside limited as large volumes years away
09/28/22 Truist
QuantumScape initiated with a Hold at Truist
07/28/22 Deutsche Bank
QuantumScape price target lowered to $13 from $20 at Deutsche Bank
07/14/22 Morgan Stanley
QuantumScape price target lowered to $12 from $30 at Morgan Stanley
PRTA Prothena
$62.61 /

+2.02 (+3.33%)

09/29/22 Oppenheimer
Prothena price target raised to $110 from $100 at Oppenheimer
09/28/22 BofA
Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis
09/28/22 RBC Capital
Prothena price target raised to $52 from $45 at RBC Capital
09/28/22 BofA
Prothena upgraded to Buy from Neutral at BofA
LCID Lucid Group
$13.69 /

-0.275 (-1.97%)

09/27/22 Cantor Fitzgerald
Lucid Group initiated with an Overweight at Cantor Fitzgerald
09/27/22 Cantor Fitzgerald
Lucid Group initiated with an Overweight at Cantor Fitzgerald
09/15/22 Citi
Lucid Group resumed with a Buy at Citi
09/14/22 Needham
Needham starts Lucid Group at Underperform on lack of profitability
LI Li Auto
$23.51 /

+0.52 (+2.26%)

09/06/22 Morgan Stanley
September 'crunch time' for China EV makers, says Morgan Stanley
08/29/22 Morgan Stanley
Li Auto delaying deliveries of L9, says Morgan Stanley
08/08/22 CLSA
Li Auto initiated with a Buy at CLSA
06/29/22 Morgan Stanley
Li Auto capital replenishment a strategic positive, says Morgan Stanley
F Ford
$11.49 /

+0.26 (+2.32%)

10/05/22 Morgan Stanley
Ford upgraded to Overweight from Equal Weight at Morgan Stanley
TSLA Tesla
$243.40 /

-21.94 (-8.27%)

RUN Sunrun
$28.74 /

+1.15 (+4.17%)

RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

QS QuantumScape
$8.79 /

+0.385 (+4.58%)

PRTA Prothena
$62.61 /

+2.02 (+3.33%)

LI Li Auto
$23.51 /

+0.52 (+2.26%)

LEV Lion Electric
$3.03 /

+0.17 (+5.95%)

LCID Lucid Group
$13.69 /

-0.275 (-1.97%)

JKS JinkoSolar
$55.77 /

+0.4 (+0.72%)

HTZ Hertz
$16.95 /

+0.635 (+3.89%)

GM General Motors
$32.86 /

+0.71 (+2.21%)

FSLR First Solar
$134.86 /

+2.56 (+1.93%)

F Ford
$11.49 /

+0.26 (+2.32%)

BP BP
$30.07 /

+1.52 (+5.32%)

  • 28
    Jun
  • 09
    Nov
  • 10
    Nov
TSLA Tesla
$243.40 /

-21.94 (-8.27%)

RUN Sunrun
$28.74 /

+1.15 (+4.17%)

RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

LI Li Auto
$23.51 /

+0.52 (+2.26%)

LCID Lucid Group
$13.69 /

-0.275 (-1.97%)

JKS JinkoSolar
$55.77 /

+0.4 (+0.72%)

HTZ Hertz
$16.95 /

+0.635 (+3.89%)

GM General Motors
$32.86 /

+0.71 (+2.21%)

FSLR First Solar
$134.86 /

+2.56 (+1.93%)

F Ford
$11.49 /

+0.26 (+2.32%)

BP BP
$30.07 /

+1.52 (+5.32%)

TSLA Tesla
$243.40 /

-21.94 (-8.27%)

RUN Sunrun
$28.74 /

+1.15 (+4.17%)

RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

QS QuantumScape
$8.79 /

+0.385 (+4.58%)

PRTA Prothena
$62.61 /

+2.02 (+3.33%)

LI Li Auto
$23.51 /

+0.52 (+2.26%)

LEV Lion Electric
$3.03 /

+0.17 (+5.95%)

JKS JinkoSolar
$55.77 /

+0.4 (+0.72%)

IE Ivanhoe Electric
$8.68 /

+0.4 (+4.83%)

HTZ Hertz
$16.95 /

+0.635 (+3.89%)

GM General Motors
$32.86 /

+0.71 (+2.21%)

FSLR First Solar
$134.86 /

+2.56 (+1.93%)

BP BP
$30.07 /

+1.52 (+5.32%)

TSLA Tesla
$243.40 /

-21.94 (-8.27%)

RUN Sunrun
$28.74 /

+1.15 (+4.17%)

RIVN Rivian Automotive
$31.46 /

-1.45 (-4.41%)

RIDE Lordstown Motors
$1.73 /

-0.095 (-5.21%)

QS QuantumScape
$8.79 /

+0.385 (+4.58%)

LI Li Auto
$23.51 /

+0.52 (+2.26%)

LEV Lion Electric
$3.03 /

+0.17 (+5.95%)

LCID Lucid Group
$13.69 /

-0.275 (-1.97%)

HTZ Hertz
$16.95 /

+0.635 (+3.89%)

GM General Motors
$32.86 /

+0.71 (+2.21%)

FSLR First Solar
$134.86 /

+2.56 (+1.93%)

F Ford
$11.49 /

+0.26 (+2.32%)

BP BP
$30.07 /

+1.52 (+5.32%)

Recommendations
H.C. Wainwright sees 'silver lining' for Clene beyond 'negative headline' in ALS » 10:35
10/03/22
10/03
10:35
10/03/22
10:35
CLNN

Clene

$1.90 /

-0.91 (-32.38%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis notes after Clene announced data from its portion of the HEALEY ALS Platform Trial that the fact that both the primary endpoint of ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks are "driving investor sentiment." However, there was "an important survival signal seen at six months with the 30 mg dose" and concurrence was seen in comparing the entirety of the HEALEY placebo groups and the placebo arm of just CNMAu8, said Pantginis, who calls this an "important silver lining" beyond the "negative headline." Though the shares are "seeing some obvious weakness on today's news," the HEALEY trial has delivered dose, safety, and a further argument for a survival benefit conferred by CNM-Au8, argues Pantginis, who reiterates a Buy rating and $16 price target on Clene shares. In early trading, Clene shares are down 90c, or 32%, to $1.90.

ShowHide Related Items >><<
CLNN Clene
$1.90 /

-0.91 (-32.38%)

CLNN Clene
$1.90 /

-0.91 (-32.38%)

07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
05/02/22 Canaccord
Clene initiated with a Buy at Canaccord
11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
CLNN Clene
$1.90 /

-0.91 (-32.38%)

CLNN Clene
$1.90 /

-0.91 (-32.38%)

CLNN Clene
$1.90 /

-0.91 (-32.38%)

CLNN Clene
$1.90 /

-0.91 (-32.38%)

Hot Stocks
Clene reports results from Healey ALS Platform trial of CNM-Au8 » 08:21
10/03/22
10/03
08:21
10/03/22
08:21
CLNN

Clene

$2.82 /

+0.015 (+0.53%)

Clene and its subsidiary…

Clene and its subsidiary Clene Nanomedicine announced topline study results showing a survival benefit in the Healey ALS Platform trial of CNM-Au8 in participants with amyotrophic lateral sclerosis. The primary endpoint of slope of change in ALS Functional Rating Scale Revised scores adjusted for mortality was not significant at 24 weeks. Secondary endpoints of Combined Assessment of Function and Survival and slow vital capacity were also not met at 24 weeks across the combined 30 mg and 60 mg CNM-Au8 doses. The prespecified exploratory analyses of the secondary survival endpoint demonstrated a greater than 90% reduction in risk of death alone or in risk of death/permanently assisted ventilation at 24 weeks, when adjusted for baseline imbalances in risk with the CNM-Au8 30 mg dose. These survival results were statistically consistent for the 30 mg dose between the regimen only and full analysis setsl. This survival signal is consistent with results previously reported by Clene in the Phase 2 RESCUE-ALS trial with CNM-Au8. The full analyses, including data on biomarkers of neurodegeneration and exploratory efficacy results, are expected later in 2022. Based on these topline findings, Clene has selected the CNM-Au8 30 mg dose for continued development in ALS. The CNM-Au8 60 mg dose did not demonstrate a survival benefit. CNM-Au8 was well-tolerated, and there were no drug-related serious adverse events or significant safety findings reported.

ShowHide Related Items >><<
CLNN Clene
$2.82 /

+0.015 (+0.53%)

CLNN Clene
$2.82 /

+0.015 (+0.53%)

07/18/22 H.C. Wainwright
Clene initiated with a Buy at H.C. Wainwright
05/02/22 Canaccord
Clene initiated with a Buy at Canaccord
11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
CLNN Clene
$2.82 /

+0.015 (+0.53%)

CLNN Clene
$2.82 /

+0.015 (+0.53%)

CLNN Clene
$2.82 /

+0.015 (+0.53%)

CLNN Clene
$2.82 /

+0.015 (+0.53%)

Recommendations
Illinois Tool Works price target lowered to $172 from $179 at Barclays » 06:16
10/03/22
10/03
06:16
10/03/22
06:16
ITW

Illinois Tool Works

$180.59 /

-3.49 (-1.90%)

Barclays analyst Julian…

Barclays analyst Julian Mitchell lowered the firm's price target on Illinois Tool Works to $172 from $179 and keeps an Underweight rating on the shares. Demand is slowing, but at a gradual pace, for the multi-industry names into the Q3 prints, Mitchell tells investors in a research note. The analyst says many management teams are likely to soon engage in "the orderly management of decline" rather than "firefighting." Mitchell see scopes for a share price bounce over Q3 earnings, given low expectations with many valuations having returned to the June lows, but sees the overall picture as "unappealing."

ShowHide Related Items >><<
ITW Illinois Tool Works
$180.59 /

-3.49 (-1.90%)

ITW Illinois Tool Works
$180.59 /

-3.49 (-1.90%)

08/24/22 BofA
Illinois Tool Works reinstated with a Neutral at BofA
08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell at Deutsche Bank on valuation
08/15/22 Deutsche Bank
Illinois Tool Works downgraded to Sell from Hold at Deutsche Bank
08/03/22 Wells Fargo
Illinois Tool Works price target raised to $187 from $180 at Wells Fargo
ITW Illinois Tool Works
$180.59 /

-3.49 (-1.90%)

ITW Illinois Tool Works
$180.59 /

-3.49 (-1.90%)

Saturday
Hot Stocks
Li Auto delivers 11,531 vehicles in September, up 62.5% year-over-year » 10:06
10/01/22
10/01
10:06
10/01/22
10:06
LI

Li Auto

$23.00 /

-0.36 (-1.54%)

Li Auto announced that…

Li Auto announced that the company delivered 11,531 vehicles in September 2022, up 62.5% year over year. The deliveries included 10,123 Li L9s, the company's six-seat, flagship smart SUV for families, in its first full month of deliveries. The September delivery brought the Company's third quarter deliveries to 26,524, representing a 5.6% year-over-year increase. The cumulative deliveries of Li Auto vehicles reached 211,015 as of the end of September.

ShowHide Related Items >><<
LI Li Auto
$23.00 /

-0.36 (-1.54%)

LI Li Auto
$23.00 /

-0.36 (-1.54%)

09/06/22 Morgan Stanley
September 'crunch time' for China EV makers, says Morgan Stanley
08/29/22 Morgan Stanley
Li Auto delaying deliveries of L9, says Morgan Stanley
08/08/22 CLSA
Li Auto initiated with a Buy at CLSA
06/29/22 Morgan Stanley
Li Auto capital replenishment a strategic positive, says Morgan Stanley
LI Li Auto
$23.00 /

-0.36 (-1.54%)

LI Li Auto
$23.00 /

-0.36 (-1.54%)

LI Li Auto
$23.00 /

-0.36 (-1.54%)

LI Li Auto
$23.00 /

-0.36 (-1.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.